Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Conditions: HER2-negative Breast Cancer; Triple Negative Breast Cancer Interventions: Drug: Capecitabine; Drug: Carboplatin; Drug: Cisplatin; Drug: Sacituzumab govitecan Sponsors: German Breast Group; Immunomedics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials